An official website of the United States government
Home
Name
Regorafenib
Alternate Names
Stivarga
Abbreviations
None
Category
Chemotherapy
Subcategory
Multi-kinase inhibitor
NSC Number
900003
Primary Site
Breast
Colorectal
Liver
Histology
None
Remarks
Stivarga received FDA approval September 27, 2012 to treat colorectal cancer.
4/28/2017: FDA expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade.
4/28/2017: FDA expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade.
Coding
This drug should be coded
